Categories
Archives
- 2026
- 2025
- 2024
- 2023
Jan
31
Voices on Value: Supporting People Impacted by Rare Disease through an Effective Policy Landscape
Jan
16
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)
Dec
18
Charting the Future: UCB’s 2024 Achievements are Fueling our 2025 Ambitions
Dec
06
UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting
Nov
26
UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting
Nov
14
New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis
Oct
14
UCB Receives U.S. FDA Approval for 320 mg Single-Injection Device Presentations of BIMZELX® (bimekizumab-bkzx)
Sep
23
UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
Sep
05
The Legacy Continues: Celebrating Two Decades of the UCB Family Epilepsy Scholarship ProgramTM
